7/102 sources · 2 publishersUpdated Nov 4, 12:46 UTC
BioCryst posts Q3 earnings beat and raises full-year revenue outlook
BioCryst Pharmaceuticals reported third‑quarter earnings of $0.14 per share, topping analysts' estimates by $0.05. Quarterly revenue came in at $180.3 million, also above expectations. The company now projects full‑year 2026 revenue of $715 million to $730 million, higher than the consensus forecast. The results and guidance were released on November 4, 2026.
Why it matters
The earnings beat and higher revenue guidance suggest stronger demand for BioCryst’s products, which could support the stock price. The company’s outlook exceeds consensus, indicating potential upside for investors.
Key facts
- 1Q3 earnings per share were $0.14, beating estimates by $0.05. investing.com
- 2Quarterly revenue was $180.3 million. investing.com
- 3Full‑year 2026 revenue guidance was $715 million to $730 million. investing.com
- 4Q3 earnings amounted to $37.9 million. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.